Immunotherapy for the Treatment of Advanced Solid Tumor

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

April 28, 2020

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2025

Conditions
Recurrence TumorMetastatic CancerSolid Tumor
Interventions
BIOLOGICAL

TIL

On day 0, cells will be infused intravenously over 20 to 30 minutes (one to four days after the last dose of fludarabine)

DRUG

Aldesleukin

IL-2 125,000 IU/kg/day IV (based on total body weight) beginning within 24 hours of cell infusion and continuing for up to 2 weeks

DRUG

Cyclophosphamide

On day -7 and day -6: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W over 1 hr.

DRUG

Fludarabine

Days -5 to -1: Fludarabine 25 mg /m2/day IVPB daily over 30 minutes for 5 days

Trial Locations (1)

430000

RECRUITING

Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan

All Listed Sponsors
lead

Tongji Hospital

OTHER